Hip Fracture Clinical Trial
Official title:
Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture
With the development of society, aged population is growing. Hip fracture is the most common
disease for aged people. With the life being longer than before, incidence of this disease
is growing. The mortality of this disease is high—— almost 10% patients will die within 1
month, about 1/3 of patients will die within 12 months. About 20%-30% aged people who have
hip fracture will die within one year.
The damaged organs caused by excessive inflammatory is one of possible reasons to cause
higher mortality. Therefore, the investigators imagined that if they gave medicines to
patients in time to reduce the inflammatory level, the inflammatory might have less effects
on organs, and the recovery could be improved.
The investigators hypothesis on the basic research: the anti-inflammatory function of non
steroidal antiinflammatory drugs (NSAIDs) can inhibit the inflammatory level of elderly hip
fracture, so as to improve the recovery level and reduce the complicating disease and
mortality. The investigators designed a clinic study to research NSAIDS' effects on
inflammatory level and prognosis of elderly hip fracture.
With the development of society, aged population is growing. The number of the aged people
over 60 years old now reaches to 130 million. Hip fracture is the most common disease for
aged people. According to Britain's statistical data of hip fracture, the average age of
males who have hip fracture is 84 years old, and female, 83 years old, and female patients
account for 74% of all the reported cases. The disease is deadly—— when attacked almost 10%
patients die within 1 month, about 1/3 of patients die within 12 months. When seniors are
attacked by hip fracture, about 20%-30% die within one year, 25% recover to normal life
before the attack, and 55% patients become disabled in different degrees. Senile fracture
has become an important issue relating to public health, brought huge burdens to average
families. While developing very fast, our modern society has to come up with a solution to
this urgent scientific problem.
The study has shown that the increasing inflammatory cytokines after senile fracture are
independent dangerous factors of death and complications and the systemic inflammatory
response after senile fracture causes organ damage and may explain why the seniors attacked
by hip fracture are more likely to die than their peers. Therefore, we intend to give drug
therapy to patients in the early stage after the attack, to reduce the inflammatory response
of the body, thus reducing the damage of the body by the inflammatory response, and
improving the prognosis of patients.
By inhibiting cyclooxygenase COX, and in turn the arachidonic acid (AA)'s transformation
into prostaglandians (PGs) and thromboxane TXA, NSAIDs produces anti-inflammatory,
antipyretic, analgesic and anti-rheumatism actions. It has been widely applied in clinic.
According to study, there are two cyclooxygenase insomers in human body namely COX-1 and
COX-2. COX-1, which exists in normal tissues, with physiological stimulation, can stimulate
arachidonic acid to produce thromboxane A, prostaglandin e (PGE2) and prostacyclin I2
(PGI2). It can therefore protect the gastrointestinal tract, kidney, platelets, and vascular
endothelial cells, and is also called structural enzyme. COX-2 is a type of COX induced by
cytokines and produced under inflammatory stimulation, COX-2 mediates arachidonic acid to
produce PGE-2 and PGI-2. As inflammatory prostaglandin, COX-2 has inflammation-causing
effects and pain-causing effects. Its inhibition lays the pharmacological foundation for the
antipyretic, analgesic, and anti-inflammatory effects of NSAIDs
Some animal experiment has showed that the inhibitor of COX-2 reduces the inflammatory
expression of animal models after multiple severe traumas and enhances the survival rate.
Recent reports suggest that the inhibitor of COX-2 (parecoxib) can reduce pro inflammatory
cytokines after traumas, chemokine level and relieve acute lung injury. Clinic study shows
that if applying the inhibitor of COX-2 into arthroplasty, the level of systemic
inflammatory cytokines can be reduced, and a better postoperative function realized. There
has been no report about the treatment of inflammatory response by NSAID after severe
trauma.
In clinic, pain treatment has been conventional in modern wards and become a symbol of
modern wards. In the newly published British NICE clinical guidelines of hip fracture, pain
treatment of patients with hip fracture is pointed out as an appropriate method. Sufficient
pain-treating enables patients to take part in necessary activities, and undergo medical
examination, nursing care and rehabilitation. N-acethy aminophenol (paracetamol) is
recommended. In case that the alone application of N-acethy aminophenol cannot completely
relieve the pain, opiate drugs should be added. The guideline does not recommend NSAIDS
since it may induce gastrointestinal complication. However, since it overcomes the side
effect of gastrointestinal reaction, NSAIDS as a fundamental drug in pain treatment,
especially an inhibitor of COX-2 has been widely applied in the treatment of trauma pain.
But its anti-inflammatory effect has not been paid enough attention. Based on the above
findings and research foundations, we wonder that besides its analgesic effect, whether
NSAIDS has a equally beneficial anti-inflammatory effect on the excessive inflammatory
response patient with severe trauma, and senior patients with hip fracture and improve their
prognosis. Therefore, based on the fundamental research, we assume that the
anti-inflammatory effect of NSAIDs can relieve the systemic inflammatory effect of senior
patients with hip fracture, improve their prognosis, reduce incidence of complications and
deaths. Through a prospective clinical experiment, we plan to study the effect of NSAIDS on
the changes of inflammatory factors of senior patients with hip fracture, and their
prognosis.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02422355 -
A Focused Registry on the Femoral Neck System (FNS) in Patients With Femoral Neck Fractures
|
||
Completed |
NCT02197065 -
Pilot Study of Atorvastatin for Orthopedic Surgery Patients
|
Phase 2 | |
Recruiting |
NCT01934946 -
Rehabilitation Care for Hip Fracture
|
N/A | |
Terminated |
NCT01667913 -
Reliability of 6-Minutes Walking Test in Hip Fracture Patients
|
N/A | |
Completed |
NCT01714336 -
Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?
|
Phase 4 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A | |
Completed |
NCT01174589 -
Training of Patients With Hip Fracture
|
Phase 2 | |
Active, not recruiting |
NCT02362971 -
External Validity of a Randomized Trial in Patients With a Femoral Neck Fracture
|
N/A | |
Completed |
NCT02591342 -
Comparison of a Cemented, Polished Tapered Stem and an Anatomic Stem for Femoral Neck Fracture
|
N/A | |
Completed |
NCT01382875 -
The Comparison of Comprehensive Multi-disciplinary Program and Conventional Care Program on Fragility Fracture Elderly
|
Phase 3 | |
Completed |
NCT01738776 -
Nutritional Risk Factors for Hip Fracture: a Case Control Study
|
N/A | |
Suspended |
NCT00521716 -
Safety and Efficacy of the WaisFix100i for Intracapsular Femoral Fracture Fixation
|
N/A | |
Terminated |
NCT00128115 -
Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)
|
Phase 2 | |
Active, not recruiting |
NCT00345488 -
Fast Track Admittance of Hip Fracture Patients
|
Phase 4 | |
Completed |
NCT02409082 -
Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures
|
N/A | |
Recruiting |
NCT04626934 -
Cognitive Intervention and Rehabilitation Outcomes in Hip Fracture Patients
|
N/A | |
Completed |
NCT06001996 -
Comparison of Intraoperative- Postoperative Effects of Pericapsular Nerve Block and Fascia Iliaca Block in Hip Fracture
|
||
Recruiting |
NCT02635763 -
Peripheral Nerve Blocks in Elderly Patients With Hip Fracture
|
N/A | |
Completed |
NCT02190903 -
A Trial To Assess Risk of Delirium in Older Adults Undergoing Hip Fracture Surgery With Spinal or General Anesthesia
|
N/A | |
Completed |
NCT00848913 -
Strength Training After Hip Fracture Surgery
|
N/A |